Get the Stockscreener App
0.389
1.77%
-0.007
After Hours:
.38
-0.009
-2.31%
Autonomix Medical Inc stock is traded at $0.389, with a volume of 105.77K.
It is down -1.77% in the last 24 hours and up +19.69% over the past month.
Autonomix Medical Inc is a development-stage medical device company focused on advancing technologies for sensing and treating disorders of the nervous system. Its platform is designed to integrate high-sensitivity neural signal detection with targeted radiofrequency (RF) ablation, enabling a sense, treat, verify approach for nerve-targeted therapies. The Company operates in one reportable segment, which is advancing the development of technologies for sensing and treating disorders relating to the nervous system. It is initially focused on developing the technology for patients with pancreatic cancer and believes the technology has the potential to address several indications, including chronic pain management, hypertension, cardiovascular disease, and other nerve-related disorders.
See More
Previous Close:
$0.396
Open:
$0.388
24h Volume:
105.77K
Relative Volume:
0.16
Market Cap:
$4.44M
Revenue:
-
Net Income/Loss:
$-16.72M
P/E Ratio:
-0.1276
EPS:
-3.0493
Net Cash Flow:
$-12.29M
1W Performance:
+2.77%
1M Performance:
+19.69%
6M Performance:
-35.50%
1Y Performance:
-68.11%
1-Day Range:
$0.374
$0.3958
1-Week Range:
$0.361
$0.406
52-Week Range:
$0.2002
$2.6399
Autonomix Medical Inc Stock (AMIX) Company Profile
Name
Autonomix Medical Inc
Sector
Industry
Phone
832-277-7816
Address
21 WATERWAY AVENUE, SUITE 300, THE WOODLANDS
Compare AMIX vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMIX
Autonomix Medical Inc
|
0.389 | 4.54M | 0 | -16.72M | -12.29M | -3.0493 |
ABT
Abbott Laboratories
|
88.50 | 154.45B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
301.14 | 118.05B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
78.14 | 103.20B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
44.95 | 69.50B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.68 | 49.68B | 6.30B | 1.07B | 1.09B | 1.8406 |
Autonomix Medical Inc Stock (AMIX) Latest News
[10-K/A] Autonomix Medical, Inc. Amends Annual Report - Stock Titan
AMIX Q1 2026 Earnings: Narrower-than-expected loss fails to lift sharesEarnings Growth Analysis - newsline.com
AMIX Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Cost DisciplineHealthcare Earnings Report - newsline.com
Autonomix Medical, Inc. Financial Disclosures & SEC Filings - TradingView
AMIX Q1 2026 Earnings: Narrower-than-Expected Loss Driven by Disciplined Cost ManagementQuarterly Profit Report - newsline.com
Autonomix Medical Announces Release of New CEO Corner - GlobeNewswire
Autonomix Medical, Inc. (AMIX) Upgraded to Strong Buy: Here's Why - MSN
Autonomix Medical (AMIX) Faces Continued Pressure Near $0.40 Support LevelDelta Hedging - newsline.com
Autonomix Medical executive discusses cancer pain treatment data By Investing.com - Investing.com South Africa
Autonomix Medical, Inc. (AMIX) Latest Stock News & Headlines - Yahoo Finance
Autonomix Medical executive discusses cancer pain treatment data - Investing.com
Autonomix Medical Highlights Advances in Visceral Cancer Pain Treatment and Pancreatic Cancer Research in Investor Segment - Quiver Quantitative
Autonomix Medical Highlights Clinical Data Presented at Society of Surgical Oncology Annual Meeting in Virtual Investor "What This Means" Segment Featuring City of Hope Chief of Medicine - GlobeNewswire
AMIX Q1 2026 Earnings: EPS Beat Surprises as Pre-Revenue Biotech Narrows LossAnalyst Drop Coverage - newsline.com
Maxim Group Maintains Autonomix Medical(AMIX.US) With Buy Rating, Maintains Target Price $2 - Moomoo
Autonomix Medical Inc. (AMIX) Q1 2026 Earnings: EPS Surprise Delivers Narrower Loss, but Revenue Void Weighs on SharesRevenue Recognition Risk - newsline.com
Autonomix Medical, Inc.: Advancing Precision Neuro-Ablation for Pancreatic Cancer Pain with Innovative Sensing Technology and De Novo FDA Pathway 39 - Minichart
Autonomix Medical FY 2026: Revenue $0 Net loss $16.7M, EPS $(2.32) — 10-K Summary - TradingView
Autonomix Medical, Inc. Reports Earnings Results for the Full Year Ended March 31, 2026 - marketscreener.com
Autonomix Medical (NASDAQ: AMIX) outlines novel nerve device plans amid going concern risk - Stock Titan
Autonomix Medical, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Autonomix Medical (AMIX) Holds Steady Near Support as Traders Eye Resistance BreakoutLate Stage Breakouts - The Legal Advocate
Autonomix Medical Inc. (AMIX) Edges Higher as Key Support Level HoldsSector Leader Stocks - Newser
Autonomix (AMIX) Jumps +8.71% on Strong Momentum 2026-05-20Ichimoku Kumo Twist - Newser
Autonomix Medical, Inc. Granted U.S. Patent for Transvascular Monitoring and Treatment Systems with Real-Time Procedural Validation - marketscreener.com
Autonomix Medical, Inc. Granted U.S. Patent for - GlobeNewswire
Autonomix Medical Announces Abstract Acceptances at EuroPCR 2026 Showcasing Long-Term Data in Pancreatic Cancer Pain Mitigation - Sahm
Why Is Autonomix Medical, Inc. Common Stock (AMIX) Stock Down Today? - Meyka
New Autonomix patent aims for real-time feedback in nerve procedures - Stock Titan
Autonomix Medical announces abstract acceptances at EuroPCR 2026 showcasing long-term data in pancreatic cancer pain mitigation - marketscreener.com
Autonomix Medical Announces Abstract Acceptances At Europcr 2026 Showcasing Long-Term Data In Pancreatic Cancer Pain Mitigation - TradingView
Autonomix Medical to present new pancreatic cancer pain relief data at EuroPCR 2026 in Paris - Pluang
Autonomix Medical Announces Abstract Acceptances at EuroPCR - GlobeNewswire
TradingKey - TradingKey
AMIX Stock Chart | AUTONOMIX MEDICAL INC (NASDAQ:AMIX) - ChartMill
AMIX: Autonomix Medical, Inc.Interactive Chart - Zacks Investment Research
Number of shareholders of Autonomix Medical, Inc. – NASDAQ:AMIX - TradingView
How Autonomix (AMIX) stacks up against analyst expectations (Flirts with Support) 2026-05-08Social Buzz Stocks - Newser
AMIX (Autonomix) EPS beats estimates by 39.7% but stock falls on zero revenue; investors eye commercialization timeline.Profitability - newser.com
AMIX Stock Price, Quote & Chart | AUTONOMIX MEDICAL INC (NASDAQ:AMIX) - ChartMill
Autonomix Medical Announces Abstract Acceptance At Digestive Disease Week 2026 - TradingView
Pancreatic cancer pain study from Autonomix lands DDW 2026 slot - Stock Titan
Autonomix (AMIX) Stock Factory Orders (+0.22%) 2026-04-27Put Dominated - newsline.com
Autonomix (AMIX) Innovation Pipeline | Autonomix Medical posts narrower loss with 39.7% EPS surpriseATM Offering - Cổng thông tin điện tử Tỉnh Sơn La
Autonomix Medical shares rally on positive pancreatic cancer pain data - MSN
Is Autonomix (AMIX) stock cyclical or defensive | Q1 2026: EPS Exceeds ExpectationsMost Discussed Stocks - Cổng thông tin điện tử tỉnh Tây Ninh
Autonomix Medical, Inc. to Present Long-Term Clinical Data on Transvascular RF Ablation for Pancreatic Cancer Pain at ECIO 2026 - Quiver Quantitative
Long-term pancreatic cancer pain study from Autonomix gets Basel stage - Stock Titan
Autonomix Medical to Present Long-Term Pain Mitigation Data in Pancreatic Cancer at ECIO 2026 - Yahoo Finance
Autonomix (AMIX) Stock: Forming Reversal? (-1.97%) 2026-04-20Risk Management - Xã Thanh Hà
Insider Trends: Can Autonomix Medical Inc scale operations efficiently2026 Trade Ideas & Community Verified Trade Alerts - baoquankhu1.vn
Autonomix Medical Inc Stock (AMIX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):